SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for ARQT.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical SG&A Expense (TTM) Data

View and export this data back to 2018. Start Trial.
Date Value
June 30, 2026 297.60M
March 31, 2026 284.63M
December 31, 2025 274.55M
September 30, 2025 253.18M
June 30, 2025 249.60M
March 31, 2025 238.60M
December 31, 2024 229.39M
September 30, 2024 220.46M
June 30, 2024 209.24M
March 31, 2024 197.02M
December 31, 2023 185.14M
September 30, 2023 173.49M
June 30, 2023 161.37M
March 31, 2023 143.04M
December 31, 2022 122.12M
September 30, 2022 103.83M
Date Value
June 30, 2022 84.83M
March 31, 2022 68.52M
December 31, 2021 60.97M
September 30, 2021 48.93M
June 30, 2021 38.02M
March 31, 2021 32.32M
December 31, 2020 21.34M
September 30, 2020 16.88M
June 30, 2020 13.62M
March 31, 2020 9.33M
December 31, 2019 6.61M
September 30, 2019 4.979M
June 30, 2019 3.293M
March 31, 2019 1.969M
December 31, 2018 1.22M
September 30, 2018 0.614M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 620.29M
Insmed, Inc. 893.58M
Emergent BioSolutions, Inc. 181.20M
Exelixis, Inc. 533.92M
Vertex Pharmaceuticals, Inc. 2.008B